These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009. Hawser SP J Infect; 2010 May; 60(5):401-2. PubMed ID: 20211200 [No Abstract] [Full Text] [Related]
3. A review of tigecycline--the first glycylcycline. Peterson LR Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522 [TBL] [Abstract][Full Text] [Related]
4. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of tigecycline activity in clinical isolates among Indian medical centers. Manoharan A; Chatterjee S; Madhan S; Mathai D Indian J Pathol Microbiol; 2010; 53(4):734-7. PubMed ID: 21045403 [TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353 [TBL] [Abstract][Full Text] [Related]
7. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines]. Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033 [No Abstract] [Full Text] [Related]
8. Tigecycline and colistin susceptibility of Chryseobacterium meningosepticum isolated from blood in Taiwan. Lin YT; Chan YJ; Chiu CH; Lin ML; Yu KW; Wang FD; Liu CY Int J Antimicrob Agents; 2009 Jul; 34(1):100-1. PubMed ID: 19261450 [No Abstract] [Full Text] [Related]
9. Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints. Hope R; Pllana T; James D; Warner M; Livermore DM J Antimicrob Chemother; 2010 Oct; 65(10):2262-4. PubMed ID: 20685753 [No Abstract] [Full Text] [Related]
10. Tigecycline: a single antibiotic for polymicrobial infections. Pankey GA; Steele RW Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711 [No Abstract] [Full Text] [Related]
11. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Edlund C; Nord CE Clin Microbiol Infect; 2000 Mar; 6(3):159-63. PubMed ID: 11168096 [No Abstract] [Full Text] [Related]
12. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205 [TBL] [Abstract][Full Text] [Related]
13. EUCAST technical note on tigecycline. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee Clin Microbiol Infect; 2006 Nov; 12(11):1147-9. PubMed ID: 17063597 [No Abstract] [Full Text] [Related]
14. Antimicrobial drug resistance in Taiwan. Huang YT; Hsueh PR Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S174-8. PubMed ID: 19013350 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic challenges in the era of antibiotic resistance. Lee C Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of tigecycline against gram-positive cocci: a multicentre study in Greece. Malli E; Spiliopoulou I; Kolonitsiou F; Neocleous Ch; Klapsa D; Pantelidi K; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou E; Petinaki E J Antimicrob Chemother; 2008 Nov; 62(5):1158-60. PubMed ID: 18753190 [No Abstract] [Full Text] [Related]
17. Comparative in vitro antimicrobial activity of tigecycline against clinical isolates of vancomycin-resistant enterococcus. Yemisen M; Demirel A; Mete B; Kaygusuz A; Mert A; Tabak F; Ozturk R Indian J Med Microbiol; 2009; 27(4):373-4. PubMed ID: 19736414 [No Abstract] [Full Text] [Related]
18. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea. Park YK; Choi JY; Song JH; Ko KS Int J Antimicrob Agents; 2009 Mar; 33(3):289-90. PubMed ID: 19091518 [No Abstract] [Full Text] [Related]
19. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Seifert H; Dowzicky MJ Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Liao CH; Kung HC; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Cheng YJ; Lin HC; Shi ZY; Wang LS; Chuang YC; Tsao SM; Lu CT; Liu JW; Huang CH; Hsueh PR Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]